Description

The proposed DSM‐5 will eliminate the words “abuse” and “dependence” from the diagnostic lexicon and replace them with a dimensional perspective consisting of three diagnoses: mild, moderate, or severe for each substance group. The proposed changes will also delete legal problems related to use and replace it with the construct of craving/compulsion to use. All 11 of the new criteria will be on a continuum. Those with positive findings on two or three of the 11 will receive a diagnosis of “mild” substance use disorder, those positive for three or four will receive a “moderate” diagnosis, and those with six or more positive findings will receive a diagnosis of “severe” substance use disorder.

This free webinar will examine the similarities and differences under the new DSM‐5 for alcohol, cannabis and cocaine diagnoses. We will utilize diagnostic information on a sample of more than 7,000 adults and 1,000 adolescents from structured interviews that capture elements of both diagnostic formulations. For no diagnosis or dependence, the new diagnoses will place most individuals into the "no diagnosis" and "severe" group, respectively. However, for those with a current diagnosis of abuse, substantial changes in diagnoses will be outlined. Results also indicate that all criteria are not equal in indicating a more severe condition. Clinical and policy implications will be discussed.

Learning Objectives:

As a result of participating in this webinar, you will be able to:

• describe the proposed DSM‐5 criteria and how it differs from the current DSM‐IV‐TR;
• explain why some with a current diagnosis of abuse will not receive a diagnosis with the new criteria;
• identify which diagnostic orphans (those with dependence indications but no diagnosis) will get a diagnosis in the new criteria;
• discuss the similarities and differences based on the substance under consideration;
• discuss the clinical and policy implications for DUI/DWI offenders.

Presenter:

Dr. Norman G. Hoffmann is a clinical psychologist who has evaluated behavioral health programs and provided consultations for over 35 years. He has worked with private organizations and governmental agencies in a variety of countries. Dr. Hoffmann served on an accreditation panel for the British Home Office and currently does accreditation reviews for the European Addiction Treatment Association. He has developed a variety of assessments instruments used throughout the United States, as well as in Canada, Sweden, Norway, and the United Kingdom. He has also designed student surveys to assess needs and evaluate prevention impacts. Dr. Hoffmann is the author of more than 150 publications and has held faculty appointments at the University of Texas Medical Branch, University of Minnesota and Brown University. Currently he is President of Evince Clinical Assessments and adjunct professor of psychology at Western Carolina University.

Who Should Attend:
Addiction professionals, employee assistance professionals, social workers, mental health counselors, professional counselors, psychologists andother helping professionals that are interested in learning about addiction-related matters.